Dermal fillers on FDA’s radar
This article was originally published in The Gray Sheet
Agency is putting together a "Post Market Issue Action Team" to address complaints about the long-term effects of dermal fillers, Peter Rumm, deputy director of general, restorative and neurological devices at the Office of Device Evaluation, says Sept. 17. Allergan gained expanded labeling in June for treatment effects lasting up to one year with its Juvederm Ultra and Juvederm Ultra Plus dermal fillers (1"The Gray Sheet" July 2, 2007, In Brief). BioForm Medical (Radiesse) and Artes Medical (ArteFill) are among other firms seeking longer-lasting indications
You may also be interested in...
Anti-aging dermal fillers Juvederm Ultra and Juvedermm Ultra Plus gain expanded labeling approval from FDA for treatment effects lasting up to one year - longer than any other hyaluronic acid-based filler, according to Allergan. Competing treatments include Medicis' Restylane HA-based dermal filler...
Delay to Moderna's Phase III plans adds to the biotech's rollercoaster ride, but its CEO insists it is still on track.
This week's Device Week podcast covers recent regulatory developments in Asia in the wake of COVID-19, and how regulators are adjusting to working under the pandemic. Having published two updates from our regular Asian Medtech Associations Reg Networking discussions this week, Medtech Insight speaks to Asia Regulatory Professional Association founder Jack Wong on Asian regulatory themes and South Korea's hosting of the next International Medical Device School.